How to get Mounjaro in 2026: the honest pathway

Getting Mounjaro comes down to a fact the ads gloss over: Mounjaro is a diabetes drug.The exact same medicine, aimed at weight loss, is sold under a different name — Zepbound. So “how do I get Mounjaro?” is really two questions wearing one coat, and which one you’re asking decides your whole route.

One molecule, two brands

Mounjaro (tirzepatide) was FDA-approved in 2022 to improve blood sugar in adults with type-2 diabetes.^[1] The identical molecule was later approved for chronic weight management under the name Zepbound.^[1] Same drug, same maker (Eli Lilly), two brands for two indications. That matters because insurance, savings programs and cash options all key off which brand and which purpose — not the molecule.

If you have type-2 diabetes (the on-label route)

Straightforward: a primary-care doctor or endocrinologist confirms type-2 diabetes and can prescribe Mounjaro on-label. Used for its approved purpose, commercial plans and Medicare Part D commonly cover it, subject to formulary tier and prior authorization.^[2] If your commercial plan covers it, Lilly’s savings card can bring the copay to as little as $25 for up to a 3-month prescription.^[2]

If you want it for weight loss (go to Zepbound)

A clinician can prescribe Mounjaro off-label for weight loss, but insurance generally won’t cover Mounjaro for weight loss, and the savings card is tied to the diabetes indication. The on-label answer is Zepbound — same tirzepatide, approved for obesity, and it has something Mounjaro doesn’t: a cash self-pay vial program (roughly $299–$449/month by dose) for people without coverage.^[3] See our Mounjaro vs Zepbound comparison and the Zepbound cost guide.

What it costs

Mounjaro’s list price (WAC) is $1,079.77 a month across dose strengths.^[4]Few pay that: a covered commercial plan plus the savings card lands near $25; a commercial plan that doesn’t cover it routes you to about $499/month via the card; and unlike Zepbound, there’s no dedicated Mounjaro cash-vial program, so uninsured retail cash runs close to the list price.^[2] Model the scenarios in our GLP-1 cost estimator.

What about compounded Mounjaro?

Compounded tirzepatide was a cheap shortage-era workaround that has largely ended. Tirzepatide came off the FDA shortage list in late 2024, closing the mass compounding exemption, and in 2026 the FDA moved to permanently bar it from large-scale compounding.^[5] A cheap “compounded Mounjaro” subscription is no longer a reliable or clearly-legal route — see our compounded vs branded guide.

The honest bottom line

Have type-2 diabetes? Getting Mounjaro is the easy, often-covered path — confirm the diagnosis and use the savings card if you’re commercially insured.^[2] Want it for weight loss? The real answer is Zepbound, the on-label, self-pay-friendly version of the same molecule. Either way, compare the legitimate telehealth routes in our best GLP-1 providers roundup, and ground your decision in our tirzepatide evidence guide.